CAPS recommends pancreatic cancer screening beginning at the age of 50 years or 5 years earlier than for high-risk individuals with defined familial pancreatic cancer in patients with BRCA2, ATM, and PALB2 mutations (Grade 2: probably do it) [77]. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.